- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, CAR T-Cell Therapy, Metastases: RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (clinicaltrials.gov) - May 18, 2022
P1, N=2, Terminated,
N=24 --> 2 | Trial completion date: Oct 2036 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Oct 2022 --> May 2022; CAR-T manufacturing technology can not meet the dose requirement for clinical patients.
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Jun 2, 2021
P1, N=4, Terminated,
N=24 --> 2 | Trial completion date: Oct 2036 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Oct 2022 --> May 2022; CAR-T manufacturing technology can not meet the dose requirement for clinical patients. N=24 --> 4 | Trial completion date: Nov 2021 --> May 2021 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> May 2021; Study halted prematurely
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Enrollment open: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Jul 23, 2020
P1, N=24, Recruiting,
N=24 --> 4 | Trial completion date: Nov 2021 --> May 2021 | Recruiting --> Terminated | Trial primary completion date: Nov 2021 --> May 2021; Study halted prematurely Not yet recruiting --> Recruiting
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Enrollment change: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Jun 9, 2020
P1, N=24, Not yet recruiting,
Not yet recruiting --> Recruiting N=12 --> 24
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Enrollment change, Trial withdrawal: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Feb 5, 2020
P1, N=0, Withdrawn,
N=12 --> 24 N=12 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Trial completion date, Trial initiation date, Trial primary completion date: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Oct 23, 2018
P1, N=12, Not yet recruiting,
N=12 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jan 2021 --> Dec 2021 | Initiation date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2021 --> Dec 2021
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
Trial completion date, Trial primary completion date: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Aug 16, 2018
P1, N=12, Not yet recruiting,
Trial completion date: Jan 2021 --> Dec 2021 | Initiation date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2021 --> Dec 2021 Trial completion date: Apr 2019 --> Jan 2021 | Trial primary completion date: Apr 2019 --> Jan 2021
- |||||||||| RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell
New P1 trial: CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - Jul 8, 2018
P1, N=12, Not yet recruiting,
|
